XPF -673C>T variation is associated with the susceptibility to breast cancer |
| |
| Institution: | 1. Department of Epidemiology, School of Public Health, North China University of Science and Technology, Tangshan, 063210, China;2. Department of Molecular Genetics, College of Life Science, North China University of Science and Technology, Tangshan, 063210, China;3. Department of Chemotherapy and Radiotherapy, Affiliated Tangshan Gongren Hospital, North China University of Science and Technology, Tangshan, 063000, China;4. Department of Thyroid and Breast Surgery, The First Hospital of Suqian, Suqian, 223812, China;5. Hebei Key Laboratory of Basic Medicine for Chronic Disease, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, 063210, China;1. Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda;2. Harvard Medical School, Boston, MA, United States;3. Moi University, Eldoret, Kenya;4. Academic Model Providing Access to Healthcare (AMPATH), Eldoret, Kenya;5. University of California, San Francisco, CA, United States;6. Masaka Regional Referral Hospital, Masaka, Uganda;7. Mbarara Regional Referral Hospital, Mbarara, Uganda;8. Indiana University, Indianapolis, IN, United States;1. Department of Pediatrics, Hematology-Oncology Unit, Faculty of Medicine-Ain Shams University, Cairo, Egypt;2. Department of Community, Environmental and Occupational Medicine, Faculty of Medicine -Ain Shams University, Cairo, Egypt;3. Cook Children’s Medical Center, Fortworth, TX, USA;1. Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Paediatric Oncology and Haematology, Germany;2. Charité-Universistätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Social Medicine, Epidemiology and Health Economics, Germany;3. Charité-Univesristätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Biometry and Clinical Epidemiology (iBiKE), Germany;4. St. Anna Kinderspital Vienna, Austria;5. University Hospital Hradec Králové, Czech Republic;6. University Hospital Ostrava, Czech Republic;7. University Hospital Brno, Czech Republic;8. Medical University Bialystok, Poland;9. University Hospital Motol, Prague, Czech Republic;10. Medical University Graz, Austria;11. University of Lucerne, Department of Health Sciences and Medicine, Switzerland;12. Medical University Wroclaw, Poland;13. Kepler Universitätsklinikum GmbH, Linz, Austria;14. Eastern Switzerland University of Applied Sciences, Department of Health Sciences, Institute of Applied Nursing Science, St. Gallen, Switzerland;15. Berlin Institute of Health (BIH), Berlin, Germany;1. Department of Cancer Prevention, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China;2. International Agency for Research on Cancer, Lyon, France;3. Registre du cancer de l’Isère, Grenoble, France;4. Research on Healthcare Performance (RESHAPE), INSERM U1290, Université Claude Bernard Lyon 1, Lyon, France;5. Fédération d’Endocrinologie, Groupement Hospitalier Est and Registre des Cancers Thyroïdiens du Rhône, Hospices Civils de Lyon, Lyon, France;6. Service de Chirurgie Endocrinienne, Groupement Hospitalier Sud and Registre des Cancers Thyroïdiens du Rhône, Hospices Civils de Lyon, Lyon, France;7. Claudius Regaud Institute, IUCT-Oncopole, Tarn Cancer Registry, Toulouse, France;8. Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO), Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy;9. Health data department, Lyon University Hospital, Lyon, France;1. Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran;2. The Persian Gulf Tropical Medicine Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran;3. Health Services Management Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran;4. Social Determinants of Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran;5. Gastroenterology and Hepatology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran;6. Endocrinology and Metabolism Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences Kerman, Iran;7. Modeling in Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran;1. Institute of Applied Health Sciences, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, United Kingdom;2. Research Unit for General Practice, Research Centre for Cancer Diagnosis in Primary Care (CaP), Bartholin’s Allé 2, 8000, Aarhus C, Denmark |
| |
| Abstract: | PurposeXPF variations might decrease the DNA repair capacity and further contribute to cancer development. This study aimed to investigate the association of XPF polymorphisms with risk of developing breast cancer.MethodsTCGA, the Human Protein Atlas and Kaplan-Meier plotter were used to analyze the expression of XPF in breast cancer tissues and its effect on the survival of breast cancer patients. The expression of XPF in breast cancer tissues was detected by qRT-PCR. This case-control study included 467 breast cancer patients and 467 healthy controls. The genotype of genetic variation was detected by polymerase chain reaction restriction fragment length polymorphism. Odds ratios and 95 % confidence intervals were calculated. Correlations between XPF variation and clinicopathological parameters were assessed through Kendall’s Tau-b test. The relationship between XPF gene function variation and XPF gene expression was analyzed by GTEx.ResultsThe expression of XPF in breast cancer tissues is higher than that in normal tissues. Breast cancer patients with high XPF expression have a higher relapse free survival rate (HR = 0.88, 95 % CI = 0.80−0.97), but have no effect on the overall survival rate (logrank P = 0.28). XPF -673C > T variant can reduce the risk of breast cancer patients (OR = 0.35, 95 %CI = 0.20−0.63 for codominant mode; OR = 0.66, 95 %CI = 0.51−0.85 for dominant model; OR = 0.40, 95 %CI = 0.23−0.70 for recessive model). The XPF 11985 GG genotype reduced the risk of early breast cancer (OR = 0.49, 95 %CI = 0.24−0.97), but not the risk of advanced breast cancer (OR = 1.20, 95 % CI = 0.58−2.48). XPF 11985A > G variant can also reduce the risk of ERBB2 expression in patients (OR = 0.50, 95 %CI = 0.27−0.94). There is no correlation between XPF -673C > T/XPF11985A > G variants and ER and PR. XPF -673C > T variant can reduce XPF expression (P < 0.05).ConclusionsGenetic variations of XPF gene may affect its expression and the risk of breast cancer in the Chinese population. |
| |
| Keywords: | Genetic variation Breast cancer Single nucleotide polymorphism |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
